WebMay 12, 2024 · During adjuvant chemotherapy, patients with decreased ctDNA VAF after adjuvant chemotherapy had a recurrence rate of 63.6%, compared to 92.3% in patients with increased ctDNA VAF. Conclusions: We envision that dynamic ctDNA analysis, especially in a post-ACT setting, might be used to not only reflect MRD but also to … A total of 116 NSCLC patients who received surgical resection were enrolled in the study, 13 of whom discontinued due to various reasons and were thus excluded from subsequent analyses (Fig. 1). The clinicopathological characteristics of the remaining 103 patients were summarized in Table 1 with details presented in … See more Somatic mutations were detected in 91 of the 103 patients’ tumor specimens, with a median of 2 mutations per patient (range: 1–8 mutations) (Supplementary Fig. 2). TP53 (67/91, 73.6%) … See more Currently, decision-making for ACT treatment is mainly based on risk stratification of stage and other clinical factors. In the current … See more To assess whether ctDNA positivity after surgery correlated with disease recurrence, ctDNA analysis was performed on postsurgical plasma samples (collected … See more We next investigated whether using longitudinal ctDNA analysis approach during the postsurgical disease surveillance can serve as a dynamic biomarker for more accurate recurrence monitoring. 79% … See more
Circulating tumor DNA as markers of dynamic recurrence risk and ...
WebRecurrence risk is a statistic that estimates the probability that a condition present in one or more family members will recur in another relative in the same or future generations. 5 … Webrecurrence risk: risk that a disease will occur elsewhere in a pedigree, given that at least one member of the pedigree (the proband) exhibits the disease. the poetry of slow life
Circulating tumor DNA dynamics and recurrence risk in …
WebMay 20, 2024 · Request PDF Serial circulating tumor DNA analysis to assess recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in stage III colorectal cancer patients. 3540 ... WebCirculating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer Cancer Biomarkers JAMA Oncology JAMA Network This multicenter cohort … WebNov 23, 2024 · In this clinical study, ctDNA will be detected in postoperative patients with stage Ⅱ and Ⅲ colorectal cancer to evaluate the correlation between ctDNA and the risk of postoperative recurrence. According to the dynamic changes of ctDNA after adjuvant chemotherapy, the correlation between ctDNA and postoperative DFS will be compared, … sideways sweaters